Nanjing Leads Biolabs Co Ltd (9887)의 가격은 얼마입니까?

Nanjing Leads Biolabs Co Ltd (9887)의 가격은 $9.31입니다.

Nanjing Leads Biolabs Co Ltd (9887)의 시가 총액은 무엇입니까?

Nanjing Leads Biolabs Co Ltd (9887)의 시가 총액은 $1.85B입니다.

Nanjing Leads Biolabs Co Ltd (9887) 수익

Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.

연도	수익	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

수익

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	수익	수익 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

회사

수익

수익 차이

국가